Martin Michaelis
Overview
Explore the profile of Martin Michaelis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
202
Citations
4658
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cinatl Jr J, Wass M, Michaelis M
Front Pharmacol
. 2024 Oct;
15:1455870.
PMID: 39469622
There is clinical evidence showing that the root extract EPs 7630 is a safe and effective treatment for a range of acute infectious respiratory illnesses. Moreover, EPs 7630 has been...
2.
Konig P, Eichhorn J, Suparman E, Buckreiss N, Cinatl J, Michaelis M, et al.
Biochim Biophys Acta Mol Basis Dis
. 2024 Aug;
1870(8):167448.
PMID: 39117290
The levels and activities of the DNA/RNA helicase schlafen11 (SLFN11) and the serine/threonine-protein kinase ataxia telangiectasia and Rad3-related protein (ATR) may determine cancer cell sensitivity to DNA damaging agents, including...
3.
Cinatl J, Bechtel M, Reus P, Ott M, Rothweiler F, Michaelis M, et al.
J Med Virol
. 2024 Jan;
96(1):e29354.
PMID: 38180134
The Mpox virus can cause severe disease in the susceptible population with dermatologic and systemic manifestations. Furthermore, ophthalmic manifestations of mpox infection are well documented. Topical trifluridine (TFT) eye drops...
4.
Calnan M, Kirchin S, Roberts D, Wass M, Michaelis M
Pharmacol Res
. 2023 Dec;
199:107043.
PMID: 38128855
In the life sciences, there is an ongoing discussion about a perceived 'reproducibility crisis'. However, it remains unclear to which extent the perceived lack of reproducibility is the consequence of...
5.
Gohlke L, Alahdab A, Oberhofer A, Worf K, Holdenrieder S, Michaelis M, et al.
Int J Mol Sci
. 2023 Oct;
24(19).
PMID: 37834189
Despite recent advances in the treatment of non-small cell lung cancer (NSCLC), acquired drug resistance to targeted therapy remains a major obstacle. Epithelial-mesenchymal transition (EMT) has been identified as a...
6.
Jacob M, Wiedemann S, Brucher D, Pieper N, Birkhold M, Sarchen V, et al.
Br J Cancer
. 2023 Sep;
129(10):1667-1678.
PMID: 37723317
Background: Neuroblastoma is a paediatric cancer that is characterised by poor prognosis for chemoresistant disease, highlighting the need for better treatment options. Here, we asked whether BH3-mimetics inhibiting BCL2 proteins...
7.
Menges S, Michaelis M, Kleinschmidt-Dorr K
Front Physiol
. 2023 Jul;
14:1201328.
PMID: 37435308
Osteoarthritis (OA) is a common joint disorder often affecting the knee. It is characterized by alterations of various joint tissues including subchondral bone and by chronic pain. Anti-nerve growth factor...
8.
Bojkova D, Bechtel M, Rothenburger T, Kandler J, Hayes L, Olmer R, et al.
J Med Virol
. 2023 Mar;
95(3):e28686.
PMID: 36938992
Recent findings in permanent cell lines suggested that SARS-CoV-2 Omicron BA.1 induces a stronger interferon response than Delta. Here, we show that BA.1 and BA.5 but not Delta induce an...
9.
Bojkova D, Zoller N, Tietgen M, Steinhorst K, Bechtel M, Rothenburger T, et al.
J Med Virol
. 2023 Mar;
95(3):e28652.
PMID: 36897017
The antiviral drugs tecovirimat, brincidofovir, and cidofovir are considered for mpox (monkeypox) treatment despite a lack of clinical evidence. Moreover, their use is affected by toxic side-effects (brincidofovir, cidofovir), limited...
10.
Reddin I, Fenton T, Wass M, Michaelis M
Pharmacol Res
. 2023 Jan;
188:106671.
PMID: 36681368
Cancer drug development is hindered by high clinical attrition rates, which are blamed on weak predictive power by preclinical models and limited replicability of preclinical findings. However, the technically feasible...